Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants
Open Access
- 28 June 2019
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 7 (X), 1-11
- https://doi.org/10.14218/jcth.2018.00057
Abstract
The clinical management of portal vein thrombosis (PVT) remains ambiguous due to its heterogeneous presentations and its associations with liver disease, malignancy, and hypercoagulable states. The natural history and clinical outcome of PVT are highly variable, dependent upon size, extent and degree of the thrombotic occlusion, as well as the physiological impact of patient comorbidities. While existing clinical guidelines consistently recommend low molecular weight heparin or vitamin K antagonist anticoagulation in cirrhotic patients with symptomatic acute PVT, management of asymptomatic and chronic PVT may need to be determined on a case-by-case basis, factoring in the state of underlying liver disease. In general, patients with PVT and underlying malignancy should be anticoagulated to alleviate symptoms and prevent recurrences that could disrupt the cancer management. However, existing clinical data does not support routine anticoagulation of cirrhotic patients with asymptomatic PVT in the absence of underlying cancer. While low molecular weight heparin and vitamin K antagonist remain the most commonly used agents in PVT, an emerging body of clinical evidence now suggests that direct-acting oral anticoagulants may be used safely and effectively in PVT. As such, direct-acting oral anticoagulants may offer a more convenient anticoagulation alternative for PVT management in future practice.Keywords
This publication has 100 references indexed in Scilit:
- Direct thrombolytic therapy in portal and mesenteric vein thrombosisJournal of Vascular Surgery, 2012
- Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein ThrombosisClinical Gastroenterology and Hepatology, 2012
- Splanchnic vein thrombosis: new risk factors and managementThrombosis Research, 2012
- Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- JAK2Mutations Across a Spectrum of Venous Thrombosis Cases: Table 1American Journal of Clinical Pathology, 2010
- Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver CirrhosisJournal of Clinical Gastroenterology, 2010
- Vascular disorders of the liverJournal of Hepatology, 2008
- The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 casesBlood, 2008
- Portal vein thrombosis; risk factors, clinical presentation and treatmentBMC Gastroenterology, 2007
- Recent Portal or Mesenteric Venous Thrombosis: Increased Recognition and Frequent Recanalization on Anticoagulant TherapyJournal of Hepatology, 2000